Skip to main content

Archived Comments for: Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

Back to article

  1. Acknowledgement of research support from Merck, Inc.

    Mark Wainberg, Lady Davis Institute, Jewish General Hospital

    1 April 2014

    This work should have also cited research support provided by Merck, Inc. We regret this omission.

    Mark Wainberg

    Competing interests

    I have no competing interests.

Advertisement

Retrovirology

ISSN: 1742-4690

Contact us